Top Markets
Coin of the day
Genomics BioSci & Tech. Co.,Ltd. Genomics BioSci & Tech. Co.,Ltd.

Genomics BioSci & Tech. Co.,Ltd.

4195
株式のランク #26612
Genomics BioSci & Tech. Co.,Ltd. specializes in providing a comprehensive array... Genomics BioSci & Tech. Co.,Ltd. specializes in providing a comprehensive array of services within the field of genomic sequencing. Its core offerings encompass standard and intricate DNA sequencing, including TAF-certified options, with clients also benefiting from complimentary sequencing primer and primer walking services. Beyond sequencing, the company is proficient in synthesizing peptides, genes, and oligonucleotides. Furthermore, its analytical capabilities extend to crucial laboratory services such as sample preparation, gene expression analysis, genotyping, DNA methylation analysis, and microbial identification. The firm also delivers advanced sequencing solutions, including genome-level, targeted, gene regulation, and metagenomic sequencing, alongside cutting-edge third-generation sequencing technologies. To support these services, it offers integrated sequencing platforms and streamlined workflows. Additionally, Genomics BioSci & Tech. Co.,Ltd. provides specialized diagnostic screenings, such as non-invasive prenatal testing (NIPT), spinal muscular atrophy (SMA) carrier screening, and fragile X syndrome premutation screening. Established in 2001, the company's headquarters are located in New Taipei City, Taiwan.
株価
$0.54058348
最終同期: 2026-06-04
時価総額
$39.16M
変化(1日)
2.72%
変化(1年)
-18.72%
TW
取引 Genomics BioSci & Tech. Co.,Ltd. (4195)

カテゴリー

Genomics BioSci & Tech. Co.,Ltd.(4195)の利益
2026 時点の利益 TTM: 0
Genomics BioSci & Tech. Co.,Ltd. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Genomics BioSci & Tech. Co.,Ltd. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
$-3.09B -
US
- -
CH